A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease

New England Journal of Medicine

Volumn 337, Issue 7, 1997, Pages 447-452

  Cohen, Marc ^a,i   Demers, Christine ^b   Gurfinkel, Enrique P ^c   Turpie, Alexander G G ^d   Fromell, Gregg J ^e   Goodman, Shaun ^f   Langer, Anatoly ^j   Califf, Robert M ^g   Fox, Keith A A ^h   Premmereur, Jerome ^e   Bigonzi, Frederique ^e   Stephens, Jim ^e   Weatherley, Beth ^g  

^a ALLEGHENY UNIVERSITY HOSPITALS   (United States)

^b LAVAL UNIVERSITY   (Canada)

^c Instituto de Cardiologia y Cirugia Cardiovascular   (Argentina)

^d MCMASTER UNIVERSITY   (Canada)

^e SANOFI   (France)

^f ST MICHAEL'S HOSPITAL   (Canada)

^g DUKE UNIVERSITY   (United States)

^h ROYAL INFIRMARY OF EDINBURGH   (United Kingdom)

ⁱ DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^j NONE

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ENOXAPARIN; HEPARIN;

ADULT; ARTICLE; BLEEDING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DOUBLE BLIND PROCEDURE; FEMALE; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVASCULARIZATION; RISK FACTOR; THROMBOCYTOPENIA; THROMBOSIS;

AGED; ANGINA, UNSTABLE; ASPIRIN; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; ENOXAPARIN; FEMALE; FIBRINOLYTIC AGENTS; HEMORRHAGE; HEPARIN; HUMANS; INFUSIONS, INTRAVENOUS; INJECTIONS, SUBCUTANEOUS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; RECURRENCE; RISK;

EID: 8544279582     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM199708143370702     Document Type: Article

References (29)

1. Braunwald E, Mark DB, Jones RH, et al. Unstable angina: diagnosis and management. Clinical practice guideline no. 10. Rockville, Md.: Agency for Health Care Policy and Research, 1994. (AHCPR publication no. 94-0602.)
2. Théroux P, Ouimet H, McCans J, et al. Aspirin, heparin, or both to treat acute unstable angina. N Engl J Med 1988;319:1105-11.
3. The RISC Group. Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease. Lancet 1990;336:827-30.
4. Cohen M, Adams PC, Parry G, et al. Combination antithrombotic therapy in unstable rest angina and non-Q-wave infarction in nonprior aspirin users: primary end points analysis from the ATACS trial. Circulation 1994; 89:81-8.
5. Fragmin during Instability in Coronary Artery Disease (FRISC) Study Group. Low-molecular-weight heparin during instability in coronary artery disease. Lancet 1996;347:561-8.
6. Oler A, Whooley MA, Oler I, Grady D. Adding heparin to aspirin reduces the incidence of myocardial infarction and death in patients with unstable angina: a meta-analysis. JAMA 1996;276:811-5.
7. Amman EM. Hirudin in acute myocardial infarction: Thrombolysis and Thrombin Inhibition in Myocardial infarction (TIMI) 9B trial. Circulation 1996;94:911-21.
8. Hirsh I, Levine MN. Low molecular weight heparin. Blood 1992;79:1-17.
9. Melandri G, Semprini F, Cervi V, et al. Comparison of efficacy of low molecular weight heparin (parnaparin) with that of unfractionated heparin in the presence of activated platelets in healthy subjects. Am J Cardiol 1993;72:450-4.
10. Théroux P, Waters D, Lam J, Juneau M, McCans J. Reactivation of unstable angina after the discontinuation of heparin. N Engl J Med 1992; 327:141-5.
11. Samama MM, Bara L, Gerotziafas GT. Mechanisms for the antithrombotic activity in man of low molecular weight heparins (LMWHs). Haemostasis 1994;24:105-17.
12. Warkentin TE, Levine MN, Hirsh J, et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med 1995;332:1330-5.
13. Nurmohamed MT, Rosendaal FR, Büller HR, et al. Low-molecular-weight heparin versus standard heparin in general and orthopaedic surgery: a meta-analysis. Lancet 1992;340:152-6.
14. Gurfinkel EP, Manos EJ, Mejaíl RI, et al. Low molecular weight heparin versus regular heparin or aspirin in the treatment of unstable angina and silent ischemia. J Am Coll Cardiol 1995;26:313-8.
15. Leizorovicz A, Haugh MC, Chapuis FR, Samama MM, Boissel JP. Low molecular weight heparin in prevention of perioperative thrombosis. BMJ 1992;305:913-20.
16. Prandoni P, Lensing AWA, Büller HR, et al. Comparison of subcutaneous low-molecular-weight heparin with intravenous standard heparin in proximal deep-vein thrombosis. Lancet 1992;339:441-5.
17. Hull RD, Raskob GE, Pineo GF, et al. Subcutaneous low-molecular-weight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis. N Engl J Med 1992;326:975-82.
18. Kakkar W, Cohen AT, Edmondson RA, et al. Low molecular weight versus standard heparin for prevention of venous thromboembolism after major abdominal surgery. Lancet 1993;341:259-65.
19. Leclerc JR, Geerts WH, Desjardins L, et al. Prevention of deep vein thrombosis after major knee surgery - a randomized, double-blind trial comparing a low molecular weight heparin fragment (enoxaparin) to placebo. Thromb Haemost 1992;67:417-23.
20. Spiro TE, Johnson GJ, Christie MJ, et al. Efficacy and safety of enoxaparin to prevent deep venous thrombosis after hip replacement surgery. Ann Intern Med 1994;121:81-9.
21. Levine M, Gent M, Hirsh J, et al. A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. N Engl J Med 1996;334:677-81.
22. Koopman MMW, Prandoni P, Piovella F, et al. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. N Engl J Med 1996;334:682-7.
23. Edmondson RA, Cohen AT, Das SK, Wagner MB, Kakkar VV. Low-molecular weight heparin versus aspirin and dipyridamole after femoropopliteal bypass grafting. Lancet 1994;344:914-8. [Erratum, Lancet 1994; 344:1307.]
24. Kay R, Wong KS, Yu YL, et al. Low-molecular-weight heparin for the treatment of acute ischemic stroke. N Engl J Med 1995;333:1588-93.
25. Neri Serneri GG, Modesti PA, Gensini GF, et al. Randomised comparison of subcutaneous heparin, intravenous heparin, and aspirin in unstable angina. Lancet 1995;345:1201-4.
26. Klein W, Buchwald A, Hillis SE, et al. Comparison of low-molecular-weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease: Fragmin in Unstable Coronary Artery Disease Study (FRIC). Circulation 1997;96:61-8.
27. The Thrombolysis in Myocardial Infarction (TIMI) 11A Trial Investigators. Dose-ranging trial of enoxaparin for unstable angina: results of TIMI 11A. J Am Coll Cardiol 1997;29:1474-82.
28. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIb Investigators. A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes. N Engl J Med 1996;335:775-82.
29. The PARAGON Investigators. A randomized trial of potent platelet IIb/IIIa antagonism, heparin, or both in patients with unstable angina: the PARAGON study. Circulation 1996;94:Suppl I:I-553. abstract.